Nir Barzilai
The TAME trial architect making aging an FDA indication
Bio
Nir Barzilai runs the Einstein Institute for Aging Research and is the architect of TAME (Targeting Aging with Metformin), the first trial explicitly designed to push the FDA to recognize aging as a regulatable indication. His Longevity Genes Project has studied hundreds of Ashkenazi Jewish centenarians to find genetic variants associated with exceptional longevity.
Background
Barzilai trained in medicine in Israel and built his academic career at Einstein, where he has directed the Institute for Aging Research for over two decades. He has been a central figure in the geroscience movement, arguing that targeting aging biology itself — rather than individual diseases — is the most efficient route to improving human health.
What They Do
Barzilai's two signature efforts are the Longevity Genes Project (genetic studies of centenarians) and TAME (a proposed multi-site trial of metformin in older adults with composite endpoints including diabetes, cardiovascular disease, cancer, and cognitive decline). He is also a prolific advocate for regulatory reform — arguing the FDA should permit aging-targeted indications — and for geroscience more broadly. His Age Later book presents this program for a general audience.
Research Record
Barzilai has a substantial peer-reviewed record on centenarian genetics, including identification of CETP and IGF-1 receptor variants associated with exceptional longevity. His lab's work on growth hormone pathway signaling in long-lived humans is well cited, and he is a frequent co-author on geroscience consensus papers.
Our Evidence Summary
Barzilai's centenarian work is genuinely strong science and has contributed real genetic findings to the field. The TAME trial design is legitimate and its regulatory framing is one of the most important practical contributions anyone has made to geroscience, even though results are pending. His public metformin-for-everyone advocacy runs ahead of the current evidence, particularly given recent trials suggesting metformin may blunt some exercise adaptations in non-diabetics.
Claim-by-Claim Evidence Review
Centenarian genetic studies have identified real longevity-associated variants
CETP and IGF-1 receptor variants found in the Longevity Genes Project have been replicated and tie to plausible biological mechanisms. This is solid human genetics.
The TAME trial design is a legitimate path toward regulatory recognition of aging
TAME's composite endpoint and multi-site design are carefully constructed to test the geroscience hypothesis and produce FDA-relevant data. Whether metformin is the right drug is a separate question from whether the trial design is sound.
Metformin reduces all-cause mortality in people with type 2 diabetes
Decades of observational and trial evidence support metformin's cardiovascular and mortality benefits in diabetic populations. This is one of its best-established effects.
Metformin extends lifespan or healthspan in non-diabetic adults
Observational signals are mixed; recent trials including MASTERS have raised concerns that metformin blunts exercise-induced mitochondrial adaptations. Pending TAME, recommending metformin for non-diabetic longevity is not evidence-supported.
The geroscience hypothesis — that targeting aging biology can simultaneously delay multiple diseases — is plausible
Supported by animal data and by the shared biology of age-related diseases. Human clinical validation is the missing piece, which is precisely what TAME aims to supply.
Aging should be a regulatable FDA indication
A policy position rather than a scientific claim. The argument is coherent and increasingly supported across the field, but remains contested among regulators.
Growth hormone / IGF-1 pathway inhibition promotes longevity in humans
Supported by centenarian genetics and some rodent data. Clinical application is complicated by the risks of suppressing GH/IGF-1 in adults; not yet a translatable intervention.
Related Reading
The 12 Hallmarks of Aging: A Complete Guide
The 12 hallmarks of aging provide a scientific framework for understanding why we age and where interventions might slow or reverse the process.
How Does Ozempic Work? GLP-1 Drugs Explained (2026 Guide)
How does Ozempic work? A clear 2026 guide to GLP-1 drugs, the four mechanisms behind semaglutide, and how it compares to Mounjaro and Zepbound.
Epigenetic Clocks: Measuring Your True Biological Age
Your birthday tells you your chronological age. Epigenetic clocks reveal your biological age — and why the difference matters for longevity science.